Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Pilot Study of the Effect of NM-504 Cobiotic Formulation on the Efficacy and Tolerability of Metformin in Patients With Metformin Intolerance

Trial Profile

A Pilot Study of the Effect of NM-504 Cobiotic Formulation on the Efficacy and Tolerability of Metformin in Patients With Metformin Intolerance

Status: Completed
Phase of Trial: Phase 0

Latest Information Update: 08 Aug 2014

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs NM 504 (Primary) ; Metformin
  • Indications Type 2 diabetes mellitus
  • Focus Adverse reactions
  • Acronyms ProCo-Metformin
  • Sponsors MicroBiome Therapeutics
  • Most Recent Events

    • 23 Jul 2014 Status changed from recruiting to completed as reported by ClinicalTrials.gov record.
    • 16 Dec 2013 MicroBiome Therapeutics completed bridge financing intended to support completion of this trial, according to a company media release.
    • 22 Sep 2013 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top